STOCK TITAN

Acrivon Therapeutics, Inc. - ACRV STOCK NEWS

Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.

Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical-stage biopharmaceutical company dedicated to developing precision oncology medicines. The company specializes in using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to match patients with the oncology medicines most likely to work for them. This groundbreaking approach integrates drug-regulated global proteomics with intact tissue digital imaging to create drug-specific biomarker signatures, known as OncoSignature companion diagnostics, for identifying patient responders.

The company's leading candidate, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2. This drug is currently in a potentially registrational Phase 2 trial and has received Fast Track designation from the FDA for investigating its use as monotherapy for patients with platinum-resistant ovarian or endometrial cancer. The ACR-368 OncoSignature test, which is pending regulatory approval, has shown promising results in preclinical studies and past third-party Phase 2 trials.

Additionally, Acrivon is advancing ACR-2316, a selective dual WEE1/PKMYT1 inhibitor designed using the AP3 platform. This candidate shows superior single-agent activity in preclinical studies compared to benchmark inhibitors. Acrivon plans to submit an IND for ACR-2316 in Q3 2024, with clinical study initiation expected in Q4 2024.

The company's AP3 platform not only aids in drug selection but also in rational drug design and optimization. It's engineered to measure drug effects on the tumor cell protein network, identifying resistance mechanisms and optimal drug combinations.

Recently, Acrivon has made significant strides, including FDA Breakthrough Device designation for its ACR-368 OncoSignature assay and a successful $130 million private placement financing to further fund its innovative pipeline and platform development. Acrivon's focus remains on leveraging its AP3 platform for the development of precision oncology drugs that address significant unmet medical needs, aiming to improve treatment outcomes for cancer patients worldwide.

For more updates and detailed financial information, visit Acrivon's investor relations page.

Rhea-AI Summary
Acrivon Therapeutics, Inc. has approved a grant of equity awards to an employee under its 2023 Inducement Plan. The employee received 14,475 restricted stock units (RSUs) and an option to purchase 43,425 shares of Acrivon common stock. The RSUs will vest in 25% annual increments on the first anniversary of the employee's employment, while the stock options will vest 25% on the first anniversary and in additional 2.083% installments on a monthly basis thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none
-
Rhea-AI Summary
Acrivon Therapeutics reports financial results for Q2 2023 and provides business highlights. The company made progress in clinical and preclinical development, expanded its board and executive team, and enrolled patients in a Phase 2 study. They are focused on the successful execution of the study and look forward to sharing clinical data later this year. Acrivon also highlighted the broad utility of its AP3 platform and its upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.81%
Tags
-
Rhea-AI Summary
Acrivon Therapeutics has announced the appointment of Adam D. Levy, Ph.D., M.B.A., as senior vice president and head of investor relations and corporate affairs. Dr. Levy brings more than 25 years of experience in the biopharma industry, with previous roles at Zentalis Pharmaceuticals, Turning Point Therapeutics, and Gilead Sciences. Acrivon is a clinical stage biopharmaceutical company focused on developing precision oncology medicines using its proprietary proteomics-based patient responder identification platform. The company's lead clinical candidate, ACR-368, is currently in Phase 2 registrational-intent trials for multiple solid tumors. Dr. Levy's appointment reflects Acrivon's commitment to enhancing its communications and corporate affairs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.77%
Tags
-
Rhea-AI Summary

Acrivon Therapeutics, a clinical stage biopharmaceutical company, announced that CEO Peter Blume-Jensen will participate in a fireside chat on May 2, 2023, at 3:00 p.m. ET during the H.C. Wainwright BioConnect Investor Conference in New York. The company focuses on developing precision oncology medicines using its proprietary proteomics-based platform, known as Acrivon Predictive Precision Proteomics (AP3). Acrivon’s leading candidate, ACR-368, targets CHK1 and CHK2 and is in a Phase 2 trial for various tumor types. The OncoSignature® companion diagnostics, although not yet regulatory approved, aim to identify patients likely to benefit from ACR-368. Acrivon also explores preclinical programs targeting other nodes in DNA Damage Response, including WEE1 and PKMYT1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
conferences
-
Rhea-AI Summary

Acrivon Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: ACRV), will host a virtual investor event on May 1, 2023, from 11:00 a.m. to 12:00 p.m. ET. The agenda includes a company overview, an update on the Acrivon Predictive Precision Proteomics (AP3) platform, details on the preclinical pipeline, clinical trial enrollment progress, and corporate updates.

The event can be accessed via the company’s investor website, and a replay will be available for 90 days. Acrivon focuses on precision oncology medicines, utilizing its AP3 platform for patient responder identification and developing the lead candidate ACR-368, targeting CHK1 and CHK2 in a Phase 2 trial across various tumor types. The company is also exploring additional preclinical programs targeting critical nodes in DNA Damage Response.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
conferences
Rhea-AI Summary

Acrivon Therapeutics, a clinical stage biopharmaceutical company, announced that its CEO, Peter Blume-Jensen, will participate in a fireside chat at the Stifel 2023 Targeted Oncology Days Conference on April 25, 2023, at 3:00 p.m. ET. This event will be held virtually and will focus on Acrivon’s advancements in precision oncology medicines.

Acrivon’s proprietary platform, AP3, matches patients’ tumor sensitivities to specific drugs. The company is advancing its lead candidate, ACR-368, targeting CHK1 and CHK2 in a Phase 2 trial. Acrivon also develops OncoSignature companion diagnostics to identify patients most likely to benefit from its drug candidates. A replay of the webcast will be available for 90 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
conferences

FAQ

What is the current stock price of Acrivon Therapeutics (ACRV)?

The current stock price of Acrivon Therapeutics (ACRV) is $6.55 as of November 22, 2024.

What is the market cap of Acrivon Therapeutics (ACRV)?

The market cap of Acrivon Therapeutics (ACRV) is approximately 201.5M.

What does Acrivon Therapeutics specialize in?

Acrivon Therapeutics specializes in developing precision oncology medicines using its proprietary AP3 platform to match patients with the most effective treatments.

What is Acrivon's leading drug candidate?

Acrivon's leading drug candidate is ACR-368 (prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2, currently in Phase 2 trials.

What is the Acrivon Predictive Precision Proteomics (AP3) platform?

The AP3 platform integrates drug-regulated global proteomics with intact tissue digital imaging to create drug-specific biomarker signatures, aiding in patient responder identification.

Has Acrivon received any regulatory designations for its drugs?

Yes, Acrivon's ACR-368 has received Fast Track designation from the FDA for treating platinum-resistant ovarian or endometrial cancer.

What recent achievements has Acrivon announced?

Recent achievements include FDA Breakthrough Device designation for the ACR-368 OncoSignature assay and a $130 million private placement financing.

What is the status of Acrivon's ACR-2316 drug candidate?

ACR-2316, a dual WEE1/PKMYT1 inhibitor, is in preclinical development with an IND submission expected in Q3 2024 and clinical studies beginning in Q4 2024.

How does the AP3 platform contribute to drug development?

The AP3 platform helps in measuring drug effects on the tumor cell protein network, identifying resistance mechanisms, and optimizing drug design and combinations.

What is the significance of the ACR-368 OncoSignature test?

The ACR-368 OncoSignature test identifies patients most likely to respond to ACR-368 monotherapy, aiding in personalized treatment plans.

How well-funded is Acrivon for its ongoing and future projects?

Acrivon is well-funded, with recent financing expected to support operations into the second half of 2026, providing flexibility for extended research and development.

Where can investors find more information about Acrivon?

Investors can find more detailed updates and financial information on Acrivon's investor relations page.

Acrivon Therapeutics, Inc.

Nasdaq:ACRV

ACRV Rankings

ACRV Stock Data

201.45M
18.90M
22.39%
75.98%
3.48%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WATERTOWN